NEW YORK (GenomeWeb News) – Personalized medicine firm Transgenomic today announced that it has signed a deal under which PerkinElmer will market and distribute its portfolio of molecular diagnostic oncology products in all markets outside the US.
PerkinElmer will have non-exclusive rights to sell, market, and distribute, as well as provide field service activities, for the Transgenomic products beginning Jan. 1, 2014, with an initial launch in Europe. Included in the deal is Transgenomics' CRC RAScan kit, which detects genetic mutations helpful in guiding treatment decisions for colorectal cancer, and ACE kits for use on PerkinElmer's LabChip MultiDx platform.
The CRC RAScan kit already has the CE IVD Mark, enabling it to be marketed in Europe and other regions and countries that recognize the CE Mark. Specifically, the test detects the full range of RAS mutations that are relevant to a poor response to EGFR inhibitors.
Financial terms of the arrangement were not disclosed.
Paul Kinnon, president and CEO of Transgenomic, said in a statement that PerkinElmer is "the ideal commercial collaborator for our oncology genetic testing portfolio outside of the US. This portfolio addresses a growing breadth of genetic markers important to assessing risk, prognosis and treatment of a variety of cancers."